Ethris pioneers next-generation mRNA therapeutics and vaccines using its proprietary SNIM®RNA and SNaP LNP® platforms
Ethris pioneers next-generation mRNA therapeutics and vaccines using its proprietary SNIM®RNA and SNaP LNP® platforms. The company focuses on developing mRNA-based therapeutics to prevent virus-induced exacerbations in asthma and COPD, as well as mucosal vaccines and protein replacement therapies for rare genetic disorders.